Vaccines Articles
A new study showed patients with confirmed Ebola virus disease were half as likely to die if they were vaccinated against the virus than if they were not.
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech's mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
Pfizer's PENBRAYA, a vaccine for meningococcal groups A, B, C, W and Y, has been approved by the U.S. Food and Drug Administration (FDA).
An expanded indication for ERVECO for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older has been approved by the U.S. Food and Drug Administration.
A new study conducted at the University of Texas Health Science Center at Houston found that people who received shingles and pneumonia vaccines — along with tetanus and diphtheria — had as much as a 30 percent reduced risk of developing Alzheimer's the most common type of dementia.
Pfizer's ABRYSVO, a respiratory syncytial virus (RSV) vaccine, has been approved by the U.S. Food and Drug Administration for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to 6 months of age by active immunization of pregnant women at 32 through 36 weeks gestational age.
A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.
The Centers for Disease Control and Prevention updated its schedule of recommended immunizations to include COVID-19 shots and boosters for children, adolescents and adults.
Regen BioPharma has filed a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented mRNA cancer immunotherapeutic vaccine.
The World Health Organization has prequalified the first malaria vaccine, RTS,S/AS01 (also known as Mosquirix), manufactured by GSK, bringing it closer to reaching millions more children at risk of malaria.
A study by researchers at Georgia State University's Institute of Biomedical Sciences has found a new universal flu vaccine has been found to protect against influenza B viruses that offer broad defenses against different strains and improve immune protection.
U.S. researchers have developed a new mRNA vaccine against cancer that delivers the drug directly to the lymphatic system and simulates a strong immune response.
